Patient deaths put Merck, Daiichi's ADC trial on partial hold

The FDA has placed a partial hold on a clinical trial testing Merck and Daiichi's "I-DXd" in small cell lung cancer patients due to a higher than anticipated incidence of deaths. The trial is an Antibody Drug Conjugate (ADC) study.